ODTX Stock Forecast & Price Target

Odyssey Therapeutics is attractive fundamentally because OD-001 addresses ulcerative colitis through a differentiated RIPK2 scaffolding mechanism that sits upstream of TNF, IL-23 and TL1A, offering a plausible way to overcome cytokine redundancy and biologic resistance. The Phase 2a dataset de-risks the story with a 2.6-point modified Mayo reduction, 27% remission at 20 mg BID, 61% response, and no serious adverse events, serious infections, discontinuations, or liver signals, while outcomes remained similar in advanced-therapy-experienced patients. Beyond the lead asset, the company ended 2Q26 with $433M in cash and has a deeper pipeline—led by OD-002—plus planned 2H26/2H27 catalysts that could materially broaden value.

Odyssey Therapeutics is viewed negatively because its lead asset OD-001 remains only in Phase 2a/b, leaving substantial clinical development risk, and the company faces repeated warnings that studies may miss endpoints, show lower-than-expected efficacy, or reveal safety signals. Financially, the business appears highly dilutive and loss-making, with about 48M shares post-IPO, estimated GAAP EPS of ($1.13) in 3Q26 and ($6.13) in 2026, a GAAP net loss expected until 2034, and operating cash flow negative in the near and mid-term. The outlook is further pressured by unresolved FDA registration-path uncertainty, intense competition, and likely continued equity financing needs, while the limited float and low trading volume could amplify volatility, especially around the IPO lock up expiring in early November.